Locations:
Abu Dhabi|Canada|Florida|London|Nevada|Ohio|
Gray gradientGray gradient
Cleveland Clinic icon
Consult QD logo
Search IconSearch

Heart, Vascular and Thoracic

abdominal organs within the human body

Advances and Dilemmas in Multiorgan Heart Transplantation

Highlights and insights from recent Cleveland Clinic experience

cardiac amyloidosis as seen on cardiac MRI

AI Tool Improves Accuracy of Diagnosing Cardiac Amyloidosis on MRI

Model shows promise in differentiating from hypertrophic cardiomyopathy and other conditions

medical device deployed in the human heart

Assessing Efficacy of Cerebral Embolic Protection in TAVR by Geography

Post hoc analysis of PROTECTED TAVR finds reduced stroke risk in the U.S. but not beyond

heart surgery in the operating room

A New Paradigm in Managing Ventricular Septal Rupture After Myocardial Infarction

Transvalvular LVAD support transforms emergency surgery into urgent procedure

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

postoperative ventilation tube

Clinical Assessment and Collaboration Drive Sustained Improvement in Post-CABG Prolonged Ventilation Rates

How Cleveland Clinic supported an alliance hospital to improve early extubation practices

scene from a cardiac cath lab

Care of STEMI Patients Referred for Primary PCI: Expert Consensus Statement Aims to Fill Gaps

SCAI document focuses on technical aspects of care where clear guidance had been lacking

histopathologic image of tissue from a hypertrophied heart

Myocardium Histology Predicts Long-Term Outcomes of Obstructive Hypertrophic Cardiomyopathy

High composite score in myectomy specimens signals worse prognosis

Obstructive hypertrophic cardiomyopathy

REMS Update: Mavacamten Still Effective in Treating Real-World Patients With HCM

Few patients report left ventricular dysfunction or heart failure after one year

cardiac MRI showing obstructive hypertrophic cardiomyopathy

Final VALOR-HCM Report: At 128 Weeks, Mavacamten Sustains Gains in HCM Patients

Avoidance of septal reduction therapy continues while LVEF dysfunction remains infrequent

edge of an apolipoprotein particle

Small-Interfering RNA Shows Cumulative Lp(a) Reduction With Successive Doses

Phase 2 trial of zerlasiran yields first demonstration of longer effect with each dose of an siRNA

BackPage 1 of 104Next

Advertisement

Ad